{{Rsnum
|rsid=2929973
|Gene=WISP1
|Chromosome=8
|position=133230265
|Orientation=plus
|GMAF=0.1708
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=WISP1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 1.8 | 24.8 | 73.5
| HCB | 9.5 | 51.8 | 38.7
| JPT | 5.3 | 38.1 | 56.6
| YRI | 0.0 | 8.8 | 91.2
| ASW | 1.8 | 21.1 | 77.2
| CHB | 9.5 | 51.8 | 38.7
| CHD | 8.3 | 53.2 | 38.5
| GIH | 3.0 | 25.7 | 71.3
| LWK | 0.9 | 8.2 | 90.9
| MEX | 6.9 | 25.9 | 67.2
| MKK | 0.0 | 17.3 | 82.7
| TSI | 1.0 | 24.5 | 74.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2929973
|Name_s=
|Gene_s=WISP1
|Feature=
|Evidence=PubMed ID:19926868
|Annotation=In a GWAS in two Asthma family study cohorts, this SNP was found to be significantly associated with two measures of lung function: FEV1(forced expiratory volume in one second) and FVC(forced vital capacity). Risk or phenotype-associated allele: G . Phenotype: lower values for lung function measurements. Study size/population/ethnicity: 403 parent -child trios from the Childhood Asthma Management Program (CAMP) and 583 parent-child trios from the Genetics of Asthma in Costa Rica study. Significance metric(s): combined p = 0.0005 for FEV1, 0.0004 for FVC . Type of association: GN
|Drugs=
|Drug Classes=
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA165111746
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2929973
|overall_frequency_n=112
|overall_frequency_d=128
|overall_frequency=0.875
|n_genomes=54
|n_genomes_annotated=0
|n_haplomes=98
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23315860
|Title=Genetic variations in the Wnt signaling pathway affect lung function in asthma patients
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}